Biocon is targeting $1 billion revenue by the next fiscal and is betting big on small molecules and generic formulations, biosimilars, branded formulations and research services. The Bengaluru-based firm, which has been chasing the target since 2011, has identified these verticals as its key focus areas. The company had posted a revenue of Rs 4,078.7 crore in 2016-17.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
